Hematology Expert Review

Hematologic Malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed A. Abutalib, MD, and L. Jeffrey Medeiros, MD  / July 25, 2018

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue ma...

Hematologic Malignancies

Answers to Hematology Expert Review Questions

 / July 25, 2018

Question 1  Which of the following is one of the four major criteria for the diagnosis of essential thrombocythemia?  Correct Answer: A. Platelet count ≥ 450 × 109/L.  Expert Perspective  The diagnosis of essential thrombocythemia requires that all four major criteria or the first three major cr...

Multiple Myeloma

Updated International Myeloma Working Group Criteria: Diagnostic Challenges

Syed A. Abutalib, MD, and Ola Landgren, MD, PhD  / April 25, 2018

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Landgren review the underlying data that shaped the updated International Myeloma Working Group (IMWG) diagnostic criteria for multipl...

Hematologic Malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed A. Abutalib, MD, and L. Jeffrey Medeiros, MD  / March 10, 2018

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignancies...

Hematologic Malignancies

Answers to Hematology Expert Review Questions

Syed A. Abutalib, MD, and L. Jeffrey Medeiros, MD  / March 10, 2018

GUEST EDITORS: Dr. Abutalib is Assistant Director, Hematology and Hematopoietic Cell Transplantation Director, Hematopoietic Cell Transplant Apheresis Service, Cancer Treatment Centers of America, Zion, Illinois, Editor-in-Chief, Advances in Cell & Gene Therapy. Dr. Medeiros is Profess...

Hematologic Malignancies

Study Findings on Novel Agents in Neoplastic Hematology

Syed A. Abutalib, MD  / February 25, 2018  / 2017 ASH Annual Meeting

HERE IS AN UPDATE on four different studies featured at the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition. Topics focus on advanced systemic mastocytosis, diffuse large B-cell lymphoma (DLBCL), amyloidosis, and myeloproliferative neoplasms.  Systemic Mastocytosis  ...

Hematologic Malignancies

Recent Study Findings in CAR T-Cell Therapy for Neoplastic Malignancies

Syed A. Abutalib, MD  / December 10, 2017

Here is an update on two recent clinical trials focusing on chimeric antigen receptor (CAR) T-cell therapy for neoplastic malignancies. Highlighted are the findings from an early-phase study in refractory aggressive lymphoma and a study in chronic lymphocytic leukemia after failure of ibrutinib (Imb...

Hematologic Malignancies

New WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

Syed A. Abutalib, MD and L. Jeffrey Medeiros, MD  / December 10, 2017

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignancies...

Hematologic Malignancies

Answers to Hematology Expert Review Questions

Syed A. Abutalib, MD and L. Jeffrey Medeiros, MD  / December 10, 2017

Question 1  Which statement about epidemiology and clinical features of atypical CML is correct? Correct answer: C. Symptoms of atypical CML may be related to anemia and thrombocytopenia. Expert PerspectiveThe exact incidence of atypical CML is unknown, but the median patient age at diagnosis is ...

Hematologic Malignancies

Recent Study Findings in Hematologic Malignancies

Syed A. Abutalib, MD  / November 25, 2017

HERE IS A BRIEF LOOK at the study findings and clinical implications of several recent and important clinical trials in neoplastic hematology. Attention is focused on clonal myeloid disorders, acute lymphoblastic leukemia, lymphoma, and plasma cell dyscrasias.  Clonal Myeloid Disorders  STUDY...

Hematologic Malignancies

Recent Clinical Trials in Hematopoietic Cell Transplantation Setting for Hematologic Malignancies

Syed Abutalib, MD  / November 10, 2017

Here is a brief look at the study findings and clinical implications of several recent and important clinical trials in neoplastic hematology. Attention is focused on hematopoietic cell transplantation in a variety of hematologic malignancies, with investigations addressing the role of maintena...

Hematologic Malignancies

Autologous and Allogeneic Hematopoietic Cell Transplantation

Syed Abutalib, MD  / July 10, 2017  / 2016 ASH Annual Meeting & Exposition

HERE ARE SEVERAL ABSTRACTS selected from the proceedings of the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting clinical trials on autologous and allogeneic hematopoietic cell transplantation for various hematologic malignancies. Additional selected abstr...

Multiple Myeloma

Selected Novel Agents in Development for Multiple Myeloma

Syed Abutalib, MD  / June 10, 2017

Here are several abstracts selected from the proceedings of the 2016 America Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics for the development for patients with relapsed or refractory multiple myeloma. For full details of these study abstracts, vis...

Multiple Myeloma

Smoldering and Relapsed or Refractory Multiple Myeloma

Syed Abutalib, MD  / May 25, 2017  / 2016 ASH Annual Meeting & Exposition

Here are several abstracts selected from the proceedings of the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in smoldering and relapsed and/or refractory multiple myeloma. For the full details of these study abstracts, visit http://w...

Lymphoma

Selected Abstracts From the 2016 ASH Annual Meeting

Syed Abutalib, MD  / May 10, 2017

Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in various types of high-grade, aggressive non-Hodgkin lymphomas (NHLs), including peripheral T-cell lymphomas, central n...

Hematologic Malignancies

Update on Neoplastic Hematology: Review of Recent Clinical Trials

Syed A. Abutalib, MD  / November 25, 2016

Here is a brief look at the study findings and clinical implications of several recent and important clinical trials in neoplastic hematology. Attention is focused on myelodysplastic syndromes, multiple myeloma, and chronic lymphocytic leukemia. Myelodysplastic Syndromes Clinical Trial:  Rand...

Leukemia

Donor Selection for HLA-Matched Hematopoietic Cell Transplantation

Syed A. Abutalib, MD, and Katharina Fleischhauer, MD  / October 25, 2016

Case Study A 33-year-old white male is diagnosed with acute myeloid leukemia (AML) with complex cytogenetics. A decision is made in favor of performing allogeneic hematopoietic cell transplantation in first complete remission. The patient has a 35-year-old brother who is healthy and motivated to ...

Leukemia

Donor Selection for HLA-Matched Hematopoietic Cell Transplantation

Syed A. Abutalib, MD, and Katharina Fleischhauer, MD  / October 25, 2016

Question 1: Which statement about donor selection for allogeneic hematopoietic cell transplant is correct? Correct Answer: C. If a donor is available, the genotypic identity between the patient and his brother should be established by typing the patient’s parents; if this is not possible, the broth...

Hematologic Malignancies

Update on Neoplastic Hematology: Review of Recent Clinical Trials

Syed A. Abutalib, MD  / October 10, 2016

Here is a brief look at the study findings and clinical implications of several recent clinical trials on newer treatment options in neoplastic hematology. Attention is focused on several types of leukemia, Hodgkin lymphoma, and multiple myeloma. Leukemia Clinical Trial: INO-VATE ALL phase II...

Hematologic Malignancies

Complexities in the Diagnosis and Management of Amyloidosis

Syed A. Abutalib, MD, and Anita D’Souza, MD, MS  / July 10, 2016

Case Study A 70-year-old man is referred to your clinic for a consultation. Recently, a diagnosis of IgG monoclonal gammopathy of undetermined significance (MGUS) was established. Medical history is significant for essential hypertension, type II diabetes mellitus, hyperlipidemia, and atrial fibr...

Hematologic Malignancies

Complexities in the Diagnosis and Management of Amyloidosis

Syed A. Abutalib, MD, and Anita D’Souza, MD, MS  / July 10, 2016

Question 1: What is the next best step for this patient? Correct Answer: C. Determination of amyloid subtype. Expert Perspective Amyloidosis encompasses a heterogeneous group of diseases bound by the characteristic deposition of amyloid fibrils in soft tissues and bone marrow, and it could be eit...

Hematologic Malignancies

Updated WHO Classification of Hematologic Malignancies

Syed A. Abutalib, MD  / June 25, 2016

WHO last updated its classification of tumors of hematopoietic and lymphoid tissues with a fourth edition of its WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, in 2008, as part of a series of WHO Classification of Tumours monographs. This year, with the support of the Intern...

Hematologic Malignancies

Updated WHO Classification of Hematologic Malignancies

Syed A. Abutalib, MD  / June 25, 2016

Question 1: Which statement about the classification of tumors of hematopoietic and lymphoid tissues is true? Correct Answer: A. The revised WHO classification defines distant disease entities that can be reliably diagnosed using proposed criteria. Expert Perspective WHO last updated its classifi...

Supportive Care
Leukemia

Recent Reports on Treatment for Leukemias, Sinusoidal Obstruction Syndrome, and Graft-vs-Host Disease

Syed A. Abutalib, MD  / May 25, 2016

In this installment of Hematology Expert Review, I will summarize five studies from the recent literature addressing important questions about leukemias and their treatment, anticoagulant therapy with the new agent defibrotide (Defitelio), and the use of antilymphocyte globulin to prevent chron...

Hematologic Malignancies

Selected Abstracts From the 2016 BMT Tandem Meetings

Syed A. Abutalib, MD  / May 10, 2016

The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research and the American Society of Blood and Marrow Transplantation. Held recently in Honolulu, Hawaii, this year’s BMT Tandem Meetings drew 3,000 attendees from 35 countries...

Lymphoma

Q: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed Abutalib, MD, and Rimas V. Lukas, MD  / December 25, 2015

The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question appear on page 84 with expert commentary. In the November 10 issue of The ASCO Post, part 2 of...

Lymphoma

A: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed Abutalib, MD, and Rimas V. Lukas, MD  / December 25, 2015

Question 1: Based on the rationale for the current “standard of care” for primary diffuse large B-cell lymphoma of the CNS, what is the optimal induction therapy? Correct Answer: C. A high-dose methotrexate–based regimen. Expert Perspective Untreated primary diffuse large B-cell lymphoma of the C...

Lymphoma

Questions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed A. Abutalib, MD, and Rimas V. Lukas, MD  / November 10, 2015

The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question appear here with expert ­commentary. In the October 25 issue of The ASCO Post, part 1 of a cas...

Lymphoma

Answers: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed A. Abutalib, MD, and Rimas V. Lukas, MD  / November 10, 2015

Question 1: What is next best step in the management of this patient? Correct Answer: C. Ophthalmoscopy/slit lamp examination. Expert Perspective Ophthalmic involvement should be sought by noninvasive procedures such as slit lamp examination and ophthalmoscopy and abnormal findings must be confir...

Lymphoma

Questions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed Abutalib, MD, and Rimas V. Lukas, MD  / October 25, 2015

Hematology Expert Review is an occasional feature that includes a case report followed by questions,answers, and expert commentary. In this issue of The ASCO Post, Drs. Abutalib and Lukas present part 1 of a case report on primary diffuse large B-cell lymphoma. Part 2 will be published in an upcomin...

Lymphoma

Answers: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Syed Abutalib, MD, and Rimas V. Lukas, MD  / October 25, 2015

Question 1: What is the most likely diagnosis for this patient? Correct Answer: B. Primary central nervous system lymphoma. Expert Perspective In an immunocompetent host, the differential diagnosis of isolated or multiple brain lesion(s) includes autoimmune etiologies such as neurosarcoidosis, mu...

Hematologic Malignancies

Microangiopathic Hemolytic Anemia and Thrombocytopenia: Questions

Syed A. Abutalib, MD, and Jean M. Connors, MD  / August 25, 2015

Hematology Expert Review is an occasional feature that includes a case report followed by questions, answers, and expert commentary. In the July 25 issue of The ASCO Post, part 1 of a case report was published and focused on diagnosis (see summary below). Here, in part 2, the management of this case...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.